Emerging Data for Odronextamab in DLBCL

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,John Allan, MD

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

Now Viewing

EP: 2.Emerging Data for Odronextamab in DLBCL

Video content above is prompted by the following:

What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?